Texas Challenges Pfizer’s Covid marketing in landmark appeal over vaccine misrepresentation

In a major legal showdown that could reshape corporate accountability in public health crises, the State of Texas has filed its appeal in Texas v. Pfizer, accusing the pharmaceutical giant of deceptive marketing practices during the critical early rollout of its COVID-19 vaccine.

Filed with the Fifth Circuit Court of Appeals, the brief claims Pfizer misled the public by overstating the vaccine’s effectiveness, durability, and ability to prevent transmission, relying on limited data while omitting key context — such as the difference between relative and absolute risk reduction.

Texas argues these actions created a false sense of security and distorted public understanding, despite only two months of clinical trial data and evolving virus variants.

Texas further alleges Pfizer silenced expert dissent to protect profits, while also challenging the district court’s dismissal of the case as legally inadequate. The State insists its lawsuit is not a challenge to the FDA’s emergency use authorization but targets Pfizer’s misleading public messaging post-authorization.

Texas disputes Pfizer’s defense under the PREP Act, arguing its Deceptive Trade Practices Act claims are compatible with federal law and serve the public interest. A ruling in Texas’s favor could pave the way for other states to hold pharmaceutical firms accountable under state consumer protection laws, testing the limits of pandemic-era legal immunity.